News
Sanofi, GSK in advanced discussions with EU for COVID-19 vaccine
Sanofi and GlaxoSmithKline are in advanced discussions with the European Commission for the supply of up to 300 million doses of a COVID-19 vaccine.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Sanofi and GlaxoSmithKline are in advanced discussions with the European Commission for the supply of up to 300 million doses of a COVID-19 vaccine.